UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~Earliest ~~event~~Event ~~reported~~Reported): ~~December~~July 37, ~~2007~~2009 (June 29, 2009)

(November 29, 2007)

PROTEIN POLYMER TECHNOLOGIES, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware	~~0-19724~~	33000-~~0311631~~19724	33-0311631
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)
(State or Other Jurisdiction of Incorporation)		(Commission File Number)	(IRS Employer Identification No.)

10655 Sorrento Valley Road, San Diego, California	92121
11494 Sorrento Valley Road, San Diego, CA		92121
(Address of principal executive offices)	(Zip Code)
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone ~~telephone number~~Number, ~~including~~Including ~~area~~Area ~~code~~Code: (858) 558-6064 ~~Not Applicable (Former name or former address, if changed since last report)~~

Not Applicable

~~Check~~(Former ~~the appropriate~~Name ~~box~~or ~~below~~Former Address, if ~~the~~Changed ~~Form~~Since ~~8-K~~Last ~~filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below~~Report):

~~o Written~~Check the ~~communications~~appropriate ~~pursuant~~box below if the Form 8-K filing is intended to ~~Rule~~simultaneously satisfy ~~425~~the ~~under~~filing obligation of the ~~Securities~~registrant ~~Act~~under ~~(17~~any ~~CFR~~of the following ~~230.425)~~provisions:

~~o Soliciting material~~¨ Written communications pursuant to Rule ~~14a-12~~425 under the ~~Exchange~~Securities Act (17 CFR ~~240~~230.~~14a-12~~425)

~~o Pre-commencement communications~~¨ Soliciting material pursuant to Rule ~~14d~~ 14a-~~2(b)~~12 under the Exchange Act ( 17 CFR 240.~~14d~~14a-~~2(b~~12))

o ¨ Pre-commencement communications pursuant to Rule ~~13e~~ 14d-42(cb) under the Exchange Act (17 CFR 240.~~13e~~14d-42(cb))

~~ITEM~~¨ ~~5.02~~Pre-commencement communications ~~Departure~~pursuant ofto ~~Directors~~Rule or13e-4(c) ~~Principal~~under ~~Officers;~~the ~~Election~~Exchange ofAct ~~Directors;~~(17 ~~Appointment of Principal Officers~~CFR 240.13e-4(c))

~~(b) and (c) On November 29, 2007, William N~~Item 1.01 Entry ~~Plamondon,~~into III, our Chief Executive Officer, President and Principal Accounting Officer, and Erin Davis, our Corporate Secretary, resigned. As of that date, our board of directors appointed James B. McCarthy, who is currently one of our directors, to the positions of Interim Chief Executive Officer, Interim President and Interim Principal Accounting Officer. Mr. Plamondon is remaining as one of our directors. As of the date hereof, we have not appointed a ~~new Corporate Secretary.~~Material Agreement

~~Mr.~~On June ~~McCarthy~~29, ~~who~~2009, isSanyo 55Chemical ~~years old~~Industries, ~~has~~Ltd. ~~served~~(“Sanyo”) asforwarded ~~one~~to ofProtein ~~our directors since April~~Polymer ~~2005~~Technologies, Inc. ~~He is~~ (the ~~Chairman~~“Company”), ~~and~~a ~~Chief~~fully ~~Executive~~executed ~~Officer~~copy of ~~Gemini Consulting Group, Inc.,~~ a ~~U.S.~~License ~~based, privately held holding company that he founded in 1991.~~Agreement ~~Mr. McCarthy~~between ~~addresses~~Sanyo ~~legal, organizational~~ and ~~financial~~the ~~issues for Gemini Consulting Group clients and partners~~Company. The ~~His~~effective ~~thirty~~date ~~years~~of ~~experience in~~ the ~~health care~~Agreement ~~field has ranged from analysis and planning to senior management roles.~~is ~~He has~~June ~~over~~18, ~~thirty years experience in:~~2009.

·Pursuant to ~~developing~~the ~~hospitals~~Agreement, the Company has granted a non-exclusive, world-wide license to Sanyo of its technology, know-how, and ~~ambulatory~~intellectual ~~surgery~~property ~~centers~~relating into recombinant, ~~both~~repetitive unit proteins and peptides, for the ~~U.S.~~purposes of developing and ~~overseas;~~commercializing products related to Sanyo’s specific fields of business. The Agreement remains in effect until the expiration of the last to expire of the Company’s patents licensed by Sanyo under this Agreement.

·The Agreement ~~developing~~further ~~and~~provides ~~implementing~~the ~~hospital~~Company with initial and ~~physician~~ongoing ~~joint~~license ~~venture~~fees, technical ~~strategies;~~service and training fees, and a percentage royalty on the quarterly net sales of any new products developed by Sanyo under this Agreement.

~~· implementing domestic and international medical supply and equipment arrangements.~~SIGNATURES

~~Prior~~Pursuant to ~~forming~~ ~~Gemini Consulting Group, Inc., Mr. McCarthy was~~ the ~~Executive~~requirements ~~Vice President~~ of athe ~~Chicago-based~~Securities ~~health~~Exchange ~~care~~Act ~~consulting~~of ~~company.~~1934, Hethe ~~has~~registrant ~~also held~~has ~~positions~~duly ascaused ~~Vice~~this ~~President~~report ~~and~~to ~~General~~be ~~Manager~~signed ofon aits ~~medical~~behalf ~~device manufacturing~~by ~~company in Chicago, and spent five years in increasingly responsible planning positions with~~ the ~~Medical~~undersigned ~~Products Division of 3M~~hereunto ~~Company~~duly authorized.

Mr. McCarthy received his B.A. from the University of Notre Dame, his J.D. from the Loyola University School of Law, and his M.B.A. from the Keller Graduate School of Management. He is a member of various state and national organizations, including the American Health Lawyers Association, and the National Strategy Forum. He also serves on the National Advisory Council of the Keller Graduate School of Management, Chicago, Illinois.

	PROTEIN POLYMER TECHNOLOGIES, INC.

Date: July 7, 2009	By:	/S/ JAMES B. MCCARTHY
		James B. McCarthy Interim Chief Executive Officer

Mr. McCarthy is also a member of the Board of Directors of Hinsdale Bank & Trust Company, Hinsdale, Illinois; and Wintrust Financial Corporation (WTFC, Nasdaq), Lake Forest, Illinois; and he is Chairman of the Board of Sirigen, Inc., Santa Barbara, California.2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTEIN POLYMER TECHNOLOGIES, INC., a Delaware corporation Date: December 3, 2007 By: /s/ James B. McCarthy James B. McCarthy Chief Executive Officer

Filing Compare · PROTEIN POLYMER TECHNOLOGIES INC